MannKind Corporation has been awarded a grant from Breakthrough T1D to support the ongoing INHALE-1ST clinical study evaluating Afrezza in youth newly diagnosed with type 1 diabetes. The grant comes through Breakthrough T1D's Industry Discovery and Development Partnership program and will help fund the multi-center trial assessing safety and efficacy of Afrezza combined with once-daily basal insulin in patients aged 10 to under 18. MannKind recently completed enrollment of the pilot phase of the study, which follows participants for 13 weeks with an optional extension up to 26 weeks. The collaboration underscores growing interest in inhaled insulin as a new option for pediatric diabetes care, building on the FDA's May 2026 approval of Afrezza for patients aged 6 and older.
MannKind CorpGrant from Breakthrough T1D supports pediatric inhaled insulin trial, expanding Afrezza's potential use in youth with type 1 diabetes.